Reducing calories may help cognitive function in MS

Published Date: 02 Mar 2023

Multiple sclerosis patients who cut calories two days a week not only lost weight but also experienced better cognition and other benefits in a new study.

Read Full News

Latest News

Duchenne Drug Gets Three-month FDA Extension After New Data Submission

Capricor Therapeutics said on Monday the U.S. Food and Drug Administration had extended the review period for ⁠its experimental cell therapy for Duchenne muscular dystrophy...

Antiamyloids’ Long-Term Cognitive Benefits Questioned

A reanalysis of lecanemab and donanemab trials suggests cognitive decline accelerates in open-label extensions, matching placebo rates, and challenging claims that cognitive benefits increase over time.

Aspherical Lenslets Slow Myopia Progression in Kids

A novel spectacle lens design featuring aspherical lenslets reduced myopia progression in children by more than 70% compared with standard single-vision lenses over 24 months.

Did Vaping THC 'Wax' for 5 Days Cause This Teen Girl's Seizure?

Evidence for the effect of THC on seizure threshold is conflicting, clinicians say

What New Research Shows About Prenatal Pesticide Exposure and Autism Traits

— Chlorpyrifos and other organophosphate insecticides had no association at low exposure levels

Young Girl Dies From Rare Brain-Eating Amoeba

Louisiana experienced its first confirmed Naegleria fowleri infection since 2013

Todays Updates

Milvexian Fails to Reduce CV Events After ACS

Patients in the phase 3 LIBREXIA ACS trial showed no reduction in cardiovascular events after acute coronary syndrome.

Atorvastatin Cuts Major CV Events by 30% in Older Adults in STAREE

Statin use for primary cardiovascular prevention in adults aged 70 years or older is supported by data from STAREE, although treatment did not prolong disability-free survival.

Phase 3 Eplontersen Trial Results Disappoint

Despite a major reduction in transthyretin amyloid deposits, eplontersen, a drug that reduces TTR production, did not reduce events associated with TTR amyloidosis in a phase 3 trial.

Todays Updates

Milvexian Fails to Reduce CV Events After ACS

Patients in the phase 3 LIBREXIA ACS trial showed no reduction in cardiovascular events after acute coronary syndrome.

Atorvastatin Cuts Major CV Events by 30% in Older Adults in STAREE

Statin use for primary cardiovascular prevention in adults aged 70 years or older is supported by data from STAREE, although treatment did not prolong disability-free survival.

Phase 3 Eplontersen Trial Results Disappoint

Despite a major reduction in transthyretin amyloid deposits, eplontersen, a drug that reduces TTR production, did not reduce events associated with TTR amyloidosis in a phase 3 trial.

Latest News

Capricor Therapeutics said on Monday the U.S. Food and Drug Administration had extended the review period for ⁠its experimental cell therapy for Duchenne muscular dystrophy...

A reanalysis of lecanemab and donanemab trials suggests cognitive decline accelerates in open-label extensions, matching placebo rates, and challenging claims that cognitive benefits increase over time.

A novel spectacle lens design featuring aspherical lenslets reduced myopia progression in children by more than 70% compared with standard single-vision lenses over 24 months.

Evidence for the effect of THC on seizure threshold is conflicting, clinicians say

— Chlorpyrifos and other organophosphate insecticides had no association at low exposure levels

Louisiana experienced its first confirmed Naegleria fowleri infection since 2013

News All Time

Brain Worm Culprit in Woman's Hallucinations, Incoherent Speech

MRI uncovers neurocysticercosis in a 52-year-old woman

First-in-Class Drug for ADHD Wins FDA Approval

Triple reuptake inhibitor centanafadine is indicated for patients ages 6 years and older

FDA Scientists Raise Questions About Duchenne Drug

Agency says deramiocel did not meet phase III trial endpoints, contrary to reported data

Feds Delay Autism Meeting; Wildfire Smoke and Migraine; Mortality and MS

News and commentary from the world of neurology and neuroscience

Sugar Rationing in Early Life Linked to Lower Dementia Risk Decades Later

Long-term study looks at what happened when sugar was scarce

FDA Committee Votes Down Duchenne Drug

Agency staff and drug developer disagree on endpoints

Alzheimer's Paper Retracted; MS Before Epstein-Barr Infection; Brain Aging Map

News and commentary from the world of neurology and neuroscience

Fauci Successor Imminent; CDC Expands Outbreak List; Pesticides Linked to ALS

Health news and commentary gathered by MedPage Today staff

FDA Approves First-in-Class Narcolepsy Drug

Oveporexton treats more than symptoms, restores orexin signaling

Child Dies in Gene-Editing Trial; Wegovy & Dementia Score; RFK Jr. Questions Journal

News and commentary from the world of neurology and neuroscience

Trump Issues Controversial Order on Vaccines, Suggests Autism Link

Order calls for MMR vaccine to be split up, given at separate medical appointments

Pet Hamsters Linked to Rare Brain Disorder

Exposure was associated with autoimmune cerebellar ataxia in a hospital case-control study

CDC Warns of Severe Arboviral Disease With B-Cell Drugs

Cases have included chronic, neurodegenerative encephalitis that played out over months to years

Fact Focus: Trump's False Claims During Childhood Vaccine Order Signing

A closer look at the president's assertions

Trump's Vax Order Hands Some MAHA Voters a Win, but Gives Democrats an Attack Line

Voters can elect candidates who "stand for the science," said one physician running for Congress

CDC's Zombie Programs: Congress Funds Them, but Few People Are Left to Do the Work

Democrats say what's happening is illegal

Recommended News For You

A First in Total Larynx Transplant; 'Sniffing' Out Lung Cancer; Gen X Cancer Toll

Microplastics can cause malignant changes in lung cells

Smartphone App Detects Eye Cancers From Photos

A single bout of exercise gives results that could help cancer patients

Children with rare gliomas have new hope thanks to clinical trial results.

Advanced Solid Tumors May Benefit from Investigative Immunotherapy Combo.

Cancer death rates higher for children in neighborhoods with persistent poverty, study finds

Recommended Articles For You

Revolutionizing Cancer Treatment: Harnessing the Power of AI in Histopathology 

Toripalimab + Nab-Paclitaxel in PD-L1+ TNBC: Phase 3 TORCHLIGHT Trial Results 

Risk Assessment of Bone-Marrow Reserve Under Repeated Physiological Demands 

Uncovering the Hidden Symptoms of Parathyroid Cancer in Women 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

New therapeutic strategies raised to prevent and resist metastasis in lymph nodes of breast cancer

2.

Gatekeeping May Reduce Pediatric Cancer Trial Participation

3.

Research team uncovers the underpinnings of head and neck cancers

4.

Researchers Challenge USPSTF's Lung Cancer Screening Criteria

5.

Resection for Early Liver Cancer Tied to Improved Survival.

1.

The Latest Research on Chronic Granulomatous Disease and Promising New Treatments 

2.

Exploring the Causes and Treatments of Bacterial Keratitis: A Comprehensive Guide

3.

The Unseen Danger of Anal Cancer: How to Protect Yourself

4.

Unlocking the Potential of Red Bone Marrow in the Formation of Blood Cells

5.

Case-Based Learning on Unexpected Cytopenia Patterns Following Advanced Therapies

1.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

2.

International Cancer Conference

3.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)

2.

Navigating the Complexities of Ph Negative ALL - Part VIII

3.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part V

4.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I

5.

Navigating the Complexities of Ph Negative ALL - Part V

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot